Xeris Biopharma FY2026 EPS Estimate Boosted by HC Wainwright

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) – Analysts at HC Wainwright upped their FY2026 earnings estimates for shares of Xeris Biopharma in a research report issued to clients and investors on Friday, May 8th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of $0.07 for the year, up from their prior estimate of $0.06. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Xeris Biopharma’s current full-year earnings is $0.12 per share. HC Wainwright also issued estimates for Xeris Biopharma’s FY2028 earnings at $0.37 EPS and FY2029 earnings at $0.67 EPS.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter. The firm had revenue of $83.13 million during the quarter, compared to analysts’ expectations of $79.83 million. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%.

A number of other research firms have also recently commented on XERS. Wall Street Zen raised Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. Weiss Ratings upgraded Xeris Biopharma from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Wednesday, March 4th. Four research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.80.

Xeris Biopharma Stock Down 6.0%

XERS opened at $6.14 on Tuesday. The stock has a market cap of $1.06 billion, a price-to-earnings ratio of 102.33 and a beta of 0.85. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.50 and a current ratio of 2.12. The firm’s fifty day moving average is $5.90 and its 200 day moving average is $6.92. Xeris Biopharma has a fifty-two week low of $4.30 and a fifty-two week high of $10.08.

Insiders Place Their Bets

In related news, insider Beth Hecht sold 16,667 shares of the business’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $6.23, for a total value of $103,835.41. Following the sale, the insider directly owned 1,193,173 shares in the company, valued at approximately $7,433,467.79. The trade was a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director James Aloysius Brady sold 10,834 shares of the stock in a transaction that occurred on Monday, March 30th. The shares were sold at an average price of $5.54, for a total value of $60,020.36. Following the transaction, the director directly owned 89,166 shares of the company’s stock, valued at approximately $493,979.64. The trade was a 10.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 60,835 shares of company stock worth $367,860. 4.56% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Royal Bank of Canada increased its position in Xeris Biopharma by 1,411.2% in the first quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock worth $1,170,000 after purchasing an additional 198,984 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Xeris Biopharma by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock valued at $461,000 after purchasing an additional 3,594 shares during the last quarter. Millennium Management LLC grew its stake in shares of Xeris Biopharma by 19.0% in the 1st quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock worth $12,726,000 after buying an additional 369,420 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Xeris Biopharma by 75.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after buying an additional 1,199,435 shares in the last quarter. Finally, Caxton Associates LLP bought a new stake in shares of Xeris Biopharma in the 1st quarter worth about $170,000. 42.75% of the stock is currently owned by institutional investors.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.